Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Limited Clinical Significance of Splenectomy and Splenic Hilar Lymph Node Dissection for Type 4 Gastric Cancer

  • Kunitomo, Aina (Department of Gastroenterological Surgery, Aichi Cancer Center Hospital) ;
  • Misawa, Kazunari (Department of Gastroenterological Surgery, Aichi Cancer Center Hospital) ;
  • Ito, Yuichi (Department of Gastroenterological Surgery, Aichi Cancer Center Hospital) ;
  • Ito, Seiji (Department of Gastroenterological Surgery, Aichi Cancer Center Hospital) ;
  • Higaki, Eiji (Department of Gastroenterological Surgery, Aichi Cancer Center Hospital) ;
  • Natsume, Seiji (Department of Gastroenterological Surgery, Aichi Cancer Center Hospital) ;
  • Kinoshita, Takashi (Department of Gastroenterological Surgery, Aichi Cancer Center Hospital) ;
  • Abe, Tetsuya (Department of Gastroenterological Surgery, Aichi Cancer Center Hospital) ;
  • Komori, Koji (Department of Gastroenterological Surgery, Aichi Cancer Center Hospital) ;
  • Shimizu, Yasuhiro (Department of Gastroenterological Surgery, Aichi Cancer Center Hospital)
  • Received : 2021.09.23
  • Accepted : 2021.11.25
  • Published : 2021.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Type 4 gastric cancer (GC) has a very poor prognosis even after curative resection, and the survival benefit of splenectomy for splenic hilar lymph node (LN; #10) dissection in type 4 GC remains equivocal. This study aimed to clarify the clinical significance of splenectomy for #10 dissection in patients with type 4 GC. Materials and Methods: The data of a total of 56 patients with type 4 GC who underwent total gastrectomy with splenectomy were retrospectively analyzed. Postoperative morbidity, state of LN metastasis, survival outcomes, and therapeutic value index (TVI) of each LN station were evaluated. TVI was calculated by multiplying the incidence of LN metastasis at each nodal station and the 5-year overall survival (OS) of patients who had metastasis to each node. Results: Overall, the postoperative morbidity rate was 28.6%, and the incidence of #10 metastasis in the patients was 28.6%. The 5-year OS rate for all patients was 29.9%, and most patients developed peritoneal recurrence. Moreover, the 5-year OS rates with and without #10 metastasis were 6.7% and 39.1% (median survival time, 20.4 vs. 46.0 months; P=0.006). The TVI of #10 was as low as 1.92. Conclusions: The clinical significance of splenectomy in the dissection of #10 for type 4 GC is limited and splenectomy for splenic hilar dissection alone should be omitted.

Keywords

References

  1. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer 2021;24:1-21. https://doi.org/10.1007/s10120-020-01042-y
  2. Okajima K, Isozaki H. Splenectomy for treatment of gastric cancer: Japanese experience. World J Surg 1995;19:537-540. https://doi.org/10.1007/BF00294715
  3. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-449. https://doi.org/10.1016/S1470-2045(10)70070-X
  4. Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996;347:995-999. https://doi.org/10.1016/S0140-6736(96)90144-0
  5. Ohkura Y, Haruta S, Shindoh J, Tanaka T, Ueno M, Udagawa H. Efficacy of prophylactic splenectomy for proximal advanced gastric cancer invading greater curvature. World J Surg Oncol 2017;15:106. https://doi.org/10.1186/s12957-017-1173-9
  6. Maehara Y, Moriguchi S, Yoshida M, Takahashi I, Korenaga D, Sugimachi K. Splenectomy does not correlate with length of survival in patients undergoing curative total gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer 1991;67:3006-3009. https://doi.org/10.1002/1097-0142(19910615)67:12<3006::AID-CNCR2820671213>3.0.CO;2-V
  7. Otsuji E, Yamaguchi T, Sawai K, Okamoto K, Takahashi T. Total gastrectomy with simultaneous pancreaticosplenectomy or splenectomy in patients with advanced gastric carcinoma. Br J Cancer 1999;79:1789-1793. https://doi.org/10.1038/sj.bjc.6690285
  8. Kunisaki C, Makino H, Suwa H, Sato T, Oshima T, Nagano Y, et al. Impact of splenectomy in patients with gastric adenocarcinoma of the cardia. J Gastrointest Surg 2007;11:1039-1044. https://doi.org/10.1007/s11605-007-0186-z
  9. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer. Br J Surg 2006;93:559-563. https://doi.org/10.1002/bjs.5353
  10. Li Z, Lian B, Chen J, Song D, Zhao Q. Systematic review and meta-analysis of splenectomy in gastrectomy for gastric carcinoma. Int J Surg 2019;68:104-113. https://doi.org/10.1016/j.ijsu.2019.06.018
  11. Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, et al. Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma. Ann Surg 2017;265:277-283. https://doi.org/10.1097/SLA.0000000000001814
  12. Yokota T, Teshima S, Saito T, Kikuchi S, Kunii Y, Yamauchi H. Borrmann's type IV gastric cancer: clinicopathologic analysis. Can J Surg 1999;42:371-376.
  13. An JY, Kang TH, Choi MG, Noh JH, Sohn TS, Kim S. Borrmann type IV: an independent prognostic factor for survival in gastric cancer. J Gastrointest Surg 2008;12:1364-1369. https://doi.org/10.1007/s11605-008-0516-9
  14. Pedrazzani C, Marrelli D, Pacelli F, Di Cosmo M, Mura G, Bettarini F, et al. Gastric linitis plastica: which role for surgical resection? Gastric Cancer 2012;15:56-60. https://doi.org/10.1007/s10120-011-0063-z
  15. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011;14:101-112. https://doi.org/10.1007/s10120-011-0041-5
  16. National Cancer Institute. Cancer therapy evaluation program, common terminology criteria for adverse events, version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 [Internet]. Bethesda (MD): National Cancer Institute; 2006 [cited 2021 Sep 23]. Available from: http://ctep.cancer.gov.
  17. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. https://doi.org/10.1056/NEJMoa072252
  18. Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 1995;82:346-351. https://doi.org/10.1002/bjs.1800820321
  19. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013;48:452-458. https://doi.org/10.1038/bmt.2012.244
  20. Yura M, Yoshikawa T, Otsuki S, Yamagata Y, Morita S, Katai H, et al. The therapeutic survival benefit of splenic hilar nodal dissection for advanced proximal gastric cancer invading the greater curvature. Ann Surg Oncol 2019;26:829-835. https://doi.org/10.1245/s10434-018-07122-9
  21. Maezawa Y, Aoyama T, Yamada T, Kano K, Hayashi T, Sato T, et al. Priority of lymph node dissection for proximal gastric cancer invading the greater curvature. Gastric Cancer 2018;21:569-572. https://doi.org/10.1007/s10120-017-0775-9
  22. Nashimoto A, Yabusaki H, Matsuki A. The significance of splenectomy for advanced proximal gastric cancer. Int J Surg Oncol 2012;2012:301530. https://doi.org/10.1155/2012/301530
  23. Kosuga T, Ichikawa D, Okamoto K, Komatsu S, Shiozaki A, Fujiwara H, et al. Survival benefits from splenic hilar lymph node dissection by splenectomy in gastric cancer patients: relative comparison of the benefits in subgroups of patients. Gastric Cancer 2011;14:172-177. https://doi.org/10.1007/s10120-011-0028-2
  24. Watanabe M, Kinoshita T, Enomoto N, Shibasaki H, Nishida T. Clinical significance of splenic hilar dissection with splenectomy in advanced proximal gastric cancer: an analysis at a single institution in Japan. World J Surg 2016;40:1165-1171. https://doi.org/10.1007/s00268-015-3362-4
  25. Hayashi T, Yoshikawa T, Kamiya A, Date K, Wada T, Otsuki S, et al. Is splenectomy for dissecting splenic hilar lymph nodes justified for scirrhous gastric cancer? Gastric Cancer 2020;23:922-926. https://doi.org/10.1007/s10120-020-01063-7
  26. Guggenheim DE, Shah MA. Gastric cancer epidemiology and risk factors. J Surg Oncol 2013;107:230-236. https://doi.org/10.1002/jso.23262
  27. Jung K, Park MI, Kim SE, Park SJ. Borrmann type 4 advanced gastric cancer: focus on the development of scirrhous gastric cancer. Clin Endosc 2016;49:336-345. https://doi.org/10.5946/ce.2016.057
  28. Agnes A, Estrella JS, Badgwell B. The significance of a nineteenth century definition in the era of genomics: linitis plastica. World J Surg Oncol 2017;15:123. https://doi.org/10.1186/s12957-017-1187-3
  29. Nakamura K. Issues focused on the IIc lesion in adenocarcima of fundic gland area: from the landscape of "a way to linitis plastica". Stomach Intest 1987;22:999-1001.
  30. Takizawa T, Iwasaki Y, Koike M. Distinctive features of linitis plastica type gastric carcinoma with reference to lymphangiosis carcinomatosa. Stomach Intest 1992;27:591-598.
  31. Jafferbhoy S, Shiwani H, Rustum Q. Managing gastric linitis plastica: keep the scalpel sheathed. Sultan Qaboos Univ Med J 2013;13:451-453.
  32. Schauer M, Peiper M, Theisen J, Knoefel W. Prognostic factors in patients with diffuse type gastric cancer (linitis plastica) after operative treatment. Eur J Med Res 2011;16:29-33. https://doi.org/10.1186/2047-783X-16-1-29
  33. Endo K, Sakurai M, Kusumoto E, Uehara H, Yamaguchi S, Tsutsumi N, et al. Biological significance of localized type IV scirrhous gastric cancer. Oncol Lett 2012;3:94-99. https://doi.org/10.3892/ol.2011.454
  34. Candela FC, Urmacher C, Brennan MF. Comparison of the conventional method of lymph node staging with a comprehensive fat-clearing method for gastric adenocarcinoma. Cancer 1990;66:1828-1832. https://doi.org/10.1002/1097-0142(19901015)66:8<1828::AID-CNCR2820660830>3.0.CO;2-Z
  35. Natsugoe S, Aiko T, Shimazu H. A detailed histological study on occult metastasis of the lymph nodes. Jpn J Surg 1991;21:528-532. https://doi.org/10.1007/BF02470990